Every January, roughly 9,000 people descend on San Francisco for the JP Morgan Healthcare Conference. Analysts, fund managers, corporate executives, bankers, and advisors fill the Westin St. Francis for a week of back-to-back investor meetings, panel sessions, and satellite events that set much of the tone for healthcare investing for the year ahead.
For the companies in the room, it is a remarkable opportunity. Concentrated access to institutional capital, compressed into a few days, with an efficiency that would take months to replicate through individual investor outreach.
For the companies not in the room, it might as well not be happening at all.
How the conference circuit works
Most major investor conferences hosted by sell-side banks operate on the same basic model. The bank’s corporate access team selects which companies present and which get offered one-to-one meetings with institutional investors. The criteria vary by conference, but the underlying logic remains that same, that is – banks prioritize the companies their analysts cover.
In most cases the process is informal. An analyst advocates for companies on their coverage list, and the corporate access desk allocates slots toward those companies because institutional clients can have the most informed conversations about them. A company without coverage has no internal advocate at the bank and therefore no natural pathway into the program.
The result is that the same companies that struggle to get analyst coverage also struggle to access the conference circuit, while companies that are already well covered get invited to everything. It’s a vicious circle.
The cost of being outside the room
The JP Morgan conference is the most visible example, but the same story plays out across dozens of events throughout the year. Jefferies, Goldman Sachs, Leerink, H.C. Wainwright, UBS, and Piper Sandler all host healthcare conferences that function as concentrated meeting points for institutional capital and corporate management.
A company active across three or four of these events per year gets meaningful, repeated exposure to the investors most likely to build positions in healthcare names. A company that cannot get into any of them competes for investor attention through a much longer, slower, and less efficient route.
The impact on a company’s valuation builds up over time. Institutional investors who have never met a company’s management team, never heard its clinical data in a setting where they can ask questions, and never had a substantive conversation about its pipeline are less likely to build a meaningful position. The research showing a 5% permanent return uplift when analyst coverage is initiated partly reflects this effect: coverage creates a pathway to institutional attention, and institutional attention moves prices.
A reinforcing cycle
Analyst coverage and conference access feed each other in a cycle that is hard to break into and easy to get locked out of:
- Coverage generates conference invitations.
- Conference appearances generate investor meetings.
- Investor meetings generate liquidity.
- Liquidity makes it economic for analysts to initiate.
- Initiation generates more conference invitations.
Then the cycle repeats.
For companies already in the cycle, the system is self-sustaining. For companies outside it, breaking in requires either getting coverage first or finding alternative routes to investor access that can substitute for what the conference circuit provides.
Neither path is quick, and both require deliberate effort. Both are open to some companies more than others, which makes the coverage gap a structural problem.
What changes inside the room
Companies that have experienced both sides of this dynamic will all tell you the same story. A sell-side conference meeting arranged because an analyst advocated for the company, with an institutional client who already has context from research, is – obviously – different from cold investor outreach:
- The meetings are longer.
- The questions are meatier.
- The follow-up is more likely to lead somewhere.
- The investor arrives with a preliminary view, so the conversation starts from a more informed place.
That is the compounding advantage of being covered: the research, and the investor access that follows from it.
This is the fifth piece in our series on the healthcare coverage gap. Over the coming months, we will look at what this means for the European market, what the data shows about where the gaps are largest, and what a better-functioning system might look like.
To stay up to date on what happens at the 2027 JP Morgan Healthcare Conference, sign up to receive our daily alerts here.